Paul Thomen

Wednesday, 3 April 2013

Global Nuclear Medicine Radiopharmaceuticals Market 2017

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, North America, Japan, the Republic of Korea, and Oceania between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer’s disease, Parkinson’s disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

“Radiopharmaceuticals” come under a special class of pharmaceuticals, with stringent regulations on their use. The use of radiopharmaceuticals is expanding with the improvements in production, and increase in the number of applications. The global radiopharmaceutical market for therapy and PET & SPECT imaging was valued at $3,213 million in 2010 and is expected to reach $4,734 million by 2015, growing at a CAGR of 8.1% from 2010 to 2015. The PET & SPECT diagnosis accounted for the largest share; i.e. 90% of the global radiopharmaceutical market.

Radiopharmaceuticals have a high growth potential with the increasing incidences of cancer and cardiac diseases, requiring better imaging techniques. Targeted alpha therapy is considered to be the best form of cancer treatment. Most of the radiopharmaceuticals are used in hospitals accounting for 92% of their total market share.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

Global Radiopharmaceuticals Market

Beta emitters
Alpha emitters
Global Enriched Stable Isotopes Market
Radiopharmaceutical and Stable Isotope Markets, By Geography

Table of Content

1 Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions
2 Executive Summary
3 Market Overview 
3.1 Definition Of Radiopharmaceuticals
3.2 Evolution 40
3.3 Market Segmentation
3.3.1 Radiopharmaceuticals
3.3.2 Stable Isotopes
3.4 Market Dynamics
3.4.1 Drivers Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage Rising Awareness Of Radiopharmaceuticals To Spur Growth Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.4.2 Restraints Shorter Half-Life Of Radiopharmaceuticals Restricts Its Usage High Capital To Limit The Buying Of Scanners Stringent Regulatory Guidelines And Gmp To Negatively Impact Growth Competition From Conventional Diagnostic Procedures
3.4.3 Opportunities Potential Radioisotopes In The Pipeline High Demand In Emerging Countries 49 Alpha Radio Immunotherapy-Based Targeted Cancer Treatment Alternative Diagnostic Radiopharmaceutical Solutions Cyclotron Based Production Neurological Applications
3.4.4 Threat
4 Global Radiopharmaceuticals Market 
4.1 Introduction
4.2 Diagnostic Market
4.2.1 Opportunity Matrix
4.2.2 Single-Photon Emission Computed Tomography (Spect) Imaging Technetium-99m (Tc-99m) Tc-99m To Decide Growth Trend Of Spect Radioisotopes Factors Affecting Technetium-99m Market Technetium Can Combine With 31 Different Carrier Molecules Lack Of Availability Of Technetium Thallium-201 (Tl-201) Tl-201 Is A Potential Substitute For Tc-99m Gallium-67 (Ga-67) Fluorine-18 Might Seize Ga-67 Market Share In The Near Future Iodine (I-123) Others 110
4.2.3 Pet Radiopharmaceuticals Fluorine-18 Fdg Florbetapir
5 Radiopharmaceuticals Market, By Application/ Indication 
5.1 Introduction
5.2 Diagnostic Market
5.2.1 Spect 153 Cardiology Lymphoma Thyroid Neurology Alzheimer’s, Dementia, And Parkinson’s Disease Drives Growth Of The Neurology Spect Market Others
5.2.2 Pet Application Oncology Fdg F-18 Has Become A Gold Standard For Oncology Diagnosis Using Pet Scan Cardiology Neurology Florbetapir F-18 & Fluorodopa (F-18 Dopa) Are Potential Substitutes Of Fdg F-18 Others
5.3 Therapeutic Application
5.3.1 Thyroid 168
5.3.2 Bone Metastasis
5.3.3 Lymphoma Novel Clinical Studies Goading Lymphoma Therapy Market
5.3.4 Endocrine Tumors
5.3.5 Others
6 Enriched Stable Isotopes Market 
6.1 Introduction
6.2 Market Overview
6.2.1 Asia Accounts For Largest Market Share
6.3 Market Dynamics
6.3.1 Drivers Stable Isotopes Are Natural In Origin & Hence Safe Proteomics & System Biology, Major Factors To Boost The Growth Of Stables Medical Applications Propel Stable Isotopes Market Growth
6.3.2 Restraints Harmful Effects Of Stable Isotopes Affect Market Growth High Cost Of Stables Isotope
6.4 Enriched Stables Market, By Isotopes
6.4.1 Deuterium & O-18 Are Promising Isotopes
6.4.2 Carbon-13
6.4.3 Deuterium
6.4.4 Oxygen-18
6.4.5 Nitrogen-15
6.4.6 Other Stable Isotopes
6.5 Enriched Stables Market, By Applications
6.5.1 Diagnostic & Therapeutic
6.5.2 Research
6.5.3 Pharmaceuticals
6.5.4 Industrial Sector
7 Geographic Analysis 
7.1 Introduction
7.2 Diagnostic Market
7.2.1 North America Increasing Adoption Of Alternative Production Technologies To Make Up For The Shortage Of Mo-99
7.2.2 Europe Stringent Regulations Hindering Market Growth
7.2.3 Asia Asia Promises The Highest Cagr In The Forecast Period
7.2.4 Rest Of The World (Row)
7.3 Therapy Market
7.3.1 North America Nuclear Medicine Research Drives The Beta Emitters Market
7.3.2 Europe
7.3.3 Asia
7.3.4 Rest Of The World (Row)
7.4 Enriched Stable Isotopes Market
7.4.1 Asia
7.4.2 North America
7.4.3 Europe
7.4.4 Rest Of The World (Row)
8 Competitive Landscape 
8.1 Introduction
8.2 Mergers & Acquisitions
8.3 Agreements, Partnerships, Collaborations & Joint Ventures
8.4 Products Launch
8.5 Expansions
8.6 Other Developments
8.7 Approvals
9 Company Profiles 
(Overview, Financials, Products & Services, Strategy, & Developments)*
9.1 Bracco Imaging S.P.A.
9.2 Cambridge Isotope Laboratories, Inc.
9.3 Cardinal Health, Inc.
9.4 Covidien, Plc
9.5 Eczacibasi-Monrol
9.6 Fujifilm Holdings Corporation
9.7 Ge Healthcare (Subsidiary Of General Electric Company)
9.8 Iba Group 286
9.9 Isotec, Inc. (Sigma-Aldrich)
9.10 Lantheus Medical Imaging, Inc.
9.11 Nordion, Inc.
9.12 Ntp Radioisotopes (Pty), Ltd.
9.13 Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)
9.14 Taiyo Nippon Sanso Corporation
9.15 Urenco Limited
9.16 Rotem Industries, Ltd., Inc.
9.17 Australian Nuclear Association And Technology Organization (Ansto)
9.18 Board Of Radiation And Isotope Technology (Brit)
9.19 Institute Of Atomic Energy Polatom Radioisotope Centre
9.20 Institute Of Isotopes Co., Ltd.
9.21 Institute Of Radioelement (Ire)

For more details contact Mr. Priyank Tiwari: / +18883915441

No comments:

Post a Comment

Note: only a member of this blog may post a comment.